A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

NCT ID: NCT02730481

Last Updated: 2021-09-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-31
• Study Completion Date: 2021-05-31

Brief Summary

This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ORAXOL

Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules

Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets

Group Type: EXPERIMENTAL

Oraxol

Intervention Type: DRUG

Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.

Interventions

Oraxol

Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.

Intervention Type: DRUG

Other Intervention Names

Paclitaxel and HM30181AK-US

Eligibility Criteria

Inclusion Criteria

1. Signed written informed consent

2. ≥18 years of age

3. Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

4. Measurable disease as per RECIST v1.1 criteria

5. Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: ANC ≥1500 cells/mm3, Platelet count ≥100 x 109/L, Hemoglobin ≥9 g/dL

6. Adequate liver function as demonstrated by:Total bilirubin of ≤1.5 mg/dL or ≤2.0 mg/dL for subjects with liver metastasis, Alanine aminotransferase ≤3 x upper limit of normal (ULN) or ≤5 x ULN if liver metastasis is present, Alkaline phosphatase ≤3 x ULN or ≤5 x ULN if bone or liver metastasis is present

7. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN or creatinine clearance calculation ≥60 mL/min as calculated by the Cockcroft and Gault formula

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

9. Life expectancy of at least 3 months

10. Women must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.

11. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.

Exclusion Criteria

1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)

2. Received IPs within 30 days or 5 half lives of the first study dosing day

3. Are currently receiving other medications or radiation intended for the treatment of their malignancy

4. Women of childbearing potential who are pregnant or breastfeeding

5. Currently taking a concomitant medication

6. Require therapeutic use of anticoagulation medications

7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements

8. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption

9. History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Athenex, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

E D Kramer, MD

Role: STUDY_DIRECTOR

Kinex Pharmaceuticals Inc.

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Cancer Therapy &Research Center @ UTHSCSA

San Antonio, Texas, United States

Countries

United States

Other Identifiers

KX-ORAX-004

Identifier Type: -

Identifier Source: org_study_id